177 related articles for article (PubMed ID: 37958905)
1. Transcriptome Profiling of Cardiac Glycoside Treatment Reveals EGR1 and Downstream Proteins of MAPK/ERK Signaling Pathway in Human Breast Cancer Cells.
Pavithran H; Kumavath R; Ghosh P
Int J Mol Sci; 2023 Nov; 24(21):. PubMed ID: 37958905
[TBL] [Abstract][Full Text] [Related]
2. Lanatoside C Induces G2/M Cell Cycle Arrest and Suppresses Cancer Cell Growth by Attenuating MAPK, Wnt, JAK-STAT, and PI3K/AKT/mTOR Signaling Pathways.
Reddy D; Kumavath R; Ghosh P; Barh D
Biomolecules; 2019 Nov; 9(12):. PubMed ID: 31783627
[TBL] [Abstract][Full Text] [Related]
3. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
4. Peruvoside targets apoptosis and autophagy through MAPK Wnt/β-catenin and PI3K/AKT/mTOR signaling pathways in human cancers.
Reddy D; Kumavath R; Tan TZ; Ampasala DR; Kumar AP
Life Sci; 2020 Jan; 241():117147. PubMed ID: 31830480
[TBL] [Abstract][Full Text] [Related]
5. Peruvoside, a Cardiac Glycoside, Induces Primitive Myeloid Leukemia Cell Death.
Feng Q; Leong WS; Liu L; Chan WI
Molecules; 2016 Apr; 21(4):534. PubMed ID: 27110755
[TBL] [Abstract][Full Text] [Related]
6. TBX2 interacts with heterochromatin protein 1 to recruit a novel repression complex to EGR1-targeted promoters to drive the proliferation of breast cancer cells.
Crawford NT; McIntyre AJ; McCormick A; D'Costa ZC; Buckley NE; Mullan PB
Oncogene; 2019 Aug; 38(31):5971-5986. PubMed ID: 31253870
[TBL] [Abstract][Full Text] [Related]
7. Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.
Wenzel K; Daskalow K; Herse F; Seitz S; Zacharias U; Schenk JA; Schulz H; Hubner N; Micheel B; Schlag PM; Osterziel KJ; Ozcelik C; Scherneck S; Jandrig B
Biol Chem; 2007 May; 388(5):489-95. PubMed ID: 17516844
[TBL] [Abstract][Full Text] [Related]
8. Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment.
Kumari K; Keshari S; Sengupta D; Sabat SC; Mishra SK
BMC Cancer; 2017 Dec; 17(1):858. PubMed ID: 29246124
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Cardiac Glycosides as Potential Drugs: Current and Future Scope for Cancer Therapeutics.
Kumavath R; Paul S; Pavithran H; Paul MK; Ghosh P; Barh D; Azevedo V
Biomolecules; 2021 Aug; 11(9):. PubMed ID: 34572488
[TBL] [Abstract][Full Text] [Related]
10. Protease Nexin I is a feedback regulator of EGF/PKC/MAPK/EGR1 signaling in breast cancer cells metastasis and stemness.
Tang T; Zhu Q; Li X; Zhu G; Deng S; Wang Y; Ni L; Chen X; Zhang Y; Xia T; Zen K; Pan Y; Jin L
Cell Death Dis; 2019 Sep; 10(9):649. PubMed ID: 31501409
[TBL] [Abstract][Full Text] [Related]
11. Regulation of p130(Cas)/BCAR1 expression in tamoxifen-sensitive and tamoxifen-resistant breast cancer cells by EGR1 and NAB2.
Kumbrink J; Kirsch KH
Neoplasia; 2012 Feb; 14(2):108-20. PubMed ID: 22431919
[TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis of MDA-MB-231 Cells Treated with Fumosorinone Isolated from Insect Pathogenic Fungi.
Liu Z; Tian Y; Chen Q; Zhang G; Li C; Luo DQ
Anticancer Agents Med Chem; 2020; 20(4):417-428. PubMed ID: 31830896
[TBL] [Abstract][Full Text] [Related]
13. Crucial role for early growth response-1 in the transcriptional regulation of miR-20b in breast cancer.
Li D; Ilnytskyy Y; Kovalchuk A; Khachigian LM; Bronson RT; Wang B; Kovalchuk O
Oncotarget; 2013 Sep; 4(9):1373-87. PubMed ID: 23945289
[TBL] [Abstract][Full Text] [Related]
14. Oncogenic role of early growth response-1 in liver cancer through the regulation of the microRNA-675/sestrin 3 and the Wnt/β-catenin signaling pathway.
Zhang L; Ren R; Yang X; Ge Y; Zhang X; Yuan H
Bioengineered; 2021 Dec; 12(1):5305-5322. PubMed ID: 34409922
[TBL] [Abstract][Full Text] [Related]
15. Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer.
Naderi A; Meyer M
Breast Cancer Res; 2012 Jul; 14(4):R111. PubMed ID: 22817771
[TBL] [Abstract][Full Text] [Related]
16. A systems pharmacology approach based on oncogenic signalling pathways to determine the mechanisms of action of natural products in breast cancer from transcriptome data.
Odongo R; Demiroglu-Zergeroglu A; Çakır T
BMC Complement Med Ther; 2021 Jun; 21(1):181. PubMed ID: 34193143
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
Acconcia F
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232400
[TBL] [Abstract][Full Text] [Related]
18. A bi-stable feedback loop between GDNF, EGR1, and ERα contribute to endocrine resistant breast cancer.
Horibata S; Rice EJ; Zheng H; Mukai C; Chu T; Marks BA; Coonrod SA; Danko CG
PLoS One; 2018; 13(4):e0194522. PubMed ID: 29614078
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts.
D'Assoro AB; Leontovich A; Amato A; Ayers-Ringler JR; Quatraro C; Hafner K; Jenkins RB; Libra M; Ingle J; Stivala F; Galanis E; Salisbury JL
Int J Oncol; 2010 Nov; 37(5):1167-76. PubMed ID: 20878064
[TBL] [Abstract][Full Text] [Related]
20. Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression.
Knutson TP; Daniel AR; Fan D; Silverstein KA; Covington KR; Fuqua SA; Lange CA
Breast Cancer Res; 2012 Jun; 14(3):R95. PubMed ID: 22697792
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
